Amicus Therapeutics, Inc. FOLD shares are trading higher by $2.61 (25.5 percent) at $12.87 in Tuesday's session.
Before the open, the FDA confirmed that the company may submit a New Drug Application for Migalastat for Fabry Disease.
After a much higher open, Amicus had a brief decline to $12.30 before roaring back to make a new high for the day at $13.28. That marks the highest level for the stock since October 2015, when it peaked at $13.78.
Since making that intraday high, it has been struggling to remain in the $13.00 handle.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.